Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences demonstrates a positive financial outlook driven by the anticipated approval and launch of Trodelvy in the second half of 2026, which is expected to strengthen and diversify its oncology pipeline while achieving a 90% payer coverage goal ahead of schedule. The company is poised for substantial revenue growth, with Livdelzi projected to exceed $1 billion in peak revenue and strong sales momentum observed in its HIV franchise, with a 6% year-over-year growth forecasted for 2026. Additionally, Gilead's operational discipline and improving operating margins, alongside robust expansion in the HIV PrEP market, further support the company's favorable financial trajectory.

Bears say

Gilead Sciences has adjusted its revenue forecasts downward significantly, anticipating a decline in Veklury revenues from $1.4 billion to $1.0 billion for FY25, and projecting further reductions to $600 million by 2026, indicating a troubling trend. The cell therapy segment, which reported $458 million in revenue but saw a 6% year-over-year decrease, is expected to face ongoing competitive pressures, with guidance suggesting a 10% revenue decline in 2026. Overall, the company faces a combination of policy-related headwinds and competitive dynamics that could lead to a continued downturn in key revenue streams, further negatively impacting its financial outlook.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.